OX IDATIVE s tr e s s in the lung is im p o rtant in th e p ath ogen es is of COPD. Publis h e d data in dicate th at glucocor ticoids in h ibit
Introduction
The airw ays and alve oli of patients w ith chronic obstructive airw ays disease (COPD) are invade d w ith numerous inflammatory cells, w hich have the ability to produc e reactive ox ygen spec ie s (ROS). 1 It has bee n established that an incre ase d ox idative stress is one of the major pathogenic me chanisms. 2 ,3 Ox idative stress may oc cur e ithe r by an incre ased ex posure to ROS or by a de creased capacity of the involve d tissue to ne utralise the constantly-eme rging production of ROS. Both me chanisms see m to be involved in the development of COPD. The smoking of cigarettes is clearly related to COPD. Cigarette smoke contains se veral mole cules, w hich are ROS by themselves, and it also c ontains molecules and partic ulate s, w hich generate chemic al reactions and inflammation, w ith subse que nt ROS production. 4 A major goal in the treatme nt of COPD is the reduction of the number and /or the ac tivity of inflammatory c ells. In asthma patients, glucocortic oids have bee n ap plie d suc ce ssfully w ith this inte ntion. In the p re sent study, w e have inve stigated if a pote nt inhaled gluc oc orticoid (Flutic asone prop ionate, FP) could reduce the ROS production in COPD patients. We have se le cte d COPD patie nts w ith bronchial hyp erresponsive ness (BHR) bec ause these patients have an ex aggerated de cline of the ir lung function. We hypothe size d that inflammation and ROS production in this subgroup of COPD patie nts w ere se vere, and could be influe nce d by an inhale d gluc ocorticoid. Inflammatory c ells w ere c ollec te d by me ans of bronchoalveolar lavage (BAL), before and after tre atment w ith inhaled FP or place bo. Be sides ce ll c ounts, the ROS produc tion capability w as dete rmined in v itro . Furthermore, w e analyze d the association of ROS production c apability w ith smoking behaviour, airw ays obstruction and BHR.
Material and methods

Patients
COPD patients w ere se lected ac cording to the clinical and func tional crite ria, w hich are generally acce pte d. 5 Inclusion c riteria w ere: age be tw een 40
and 70 ye ars, c urrent smoker, FEV 1 /iVC ratio £ 70% of predicted normal value s (pred ), reve rsibility of FEV 1 < 10%pred after 750 m g te rbutaline , non-specific BHR -defined by a PC20 histamine £ 8 mg /ml -and ne gative skin tests for standard inhaled allerge ns. Refe re nce value s w ere obtaine d from ECCS standards. 6 The main ex clusion c riteria w e re a history of asthma and rec ent respiratory trac t infe ction. Any anti-inflammatory drugs, including ste roids and NSAIDs, and theophylline s w ere discontinue d. Potential candidates for this study w ere informe d about the ne gative e ffec ts of smoking, and w e offere d them the opportunity to partic ipate in a smoking-c essatio n program. The Hospital's Medical Ethic s Committe e approved the study. Written informe d c onsent w as obtained from all partic ipants.
Design of the intervention study
We p erformed a double blind, place bo-controlle d study that laste d for six months. Patients w e re randomly assigne d to e ithe r tw ic e-daily 500 m g FP or plac ebo, w hich w e re delivered via a similar diskhaler. The start of treatme nt w as immediately after the first bronchoscop y. Bronchosc opy w as repe ated at the end of the study. At intervals of four w e eks, the study participants had a che ck-up.
Bronchoscopy
The proce dure w as c arried out ac cording to international guidelines. 7 For local anae sthesia w e use d lidocaine spray and ae rosolise d ox ybuproc aine. The bronchoscope (Olympus BF 1T10 ) w as advance d into the late ral segme nt of the middle lobe, in w edge position. Lavage w as pe rforme d succ essive ly w ith 1´40 ml and 4´50 ml ste rile phosphate-buffe red saline (PBS) solution (Organon Teknika, Box tel, The Netherlands ) at body tempe rature (37°C) and pH 7.4. Aliquots w e re aspirated in tw o siliconized spec imen traps, one for the first 'bronchoalveolar frac tion' after 40 ml PBS and the sec ond 'alveolar fraction' for the rec overy of the 4´50 ml PBS. The lavage fluid w as transported to the laboratory on ice and proce sse d imme diately. The recovery of the first, bronchoalve olar frac tion app eare d to be low and insufficie nt for performing the desired ex perime nts. 6 ce lls, using the diffe renc e in V m a x in the presenc e and abse nce of SOD, the reduce d minus ox idized cytochrome-c ex tinction c oe fficie nt of 21.1 mM -1 c m -1 , and the empiric ally dete rmined light path length. Since w e found the V m a x upon stimulation w ith 80 nM PMA did not inc rease further as compared to 8 nM PMA, appare ntly the ce lls w ere alre ady max imally stimulate d at the low e st PMA conc entration. There fore, w e pre se nt these data as the mean and do not refer to the PMA conc entration.
Processing of BAL fluid
Statistical analysis
Pre-and post-inte rvention data w ere tested for significant diffe re nce w ith the paired t-te st. Diffe renc es betw e en patient groups w e re te ste d w ith either the (unpaire d ) Student t-te st or the Mann -Whitne y te st, depending upon distribution of data. Correlation studies w ere performed w ith the Spe arman rank te st. Statistical significanc e w as c onsidered at p < 0.05.
Results
From the initial 23 participants in the inte rvention study, paire d results w ere obtained from 6 FP patients and from 9 patients w ith placebo. The reasons for missing paire d data w ere insuffic ie nt rec overy of either BAL fluid or BAL cells. The p atie nt characteristic s (n = 15 ), liste d in Table 1 , show that on average these patients had mode rate ly severe obstruc tive airw ays disease and se vere BHR. Compliance w ith study medication w as high: the pe rcentage of returne d use d bliste rs w as 92.5 in the FP and 92.7 in the plac ebo group.
Differe nce s in base line charac te ristics betw ee n the FP and the plac ebo group w ere not statistic ally significant. In the placebo group, me an FEV 1 decline d from 68.5%pre d at the start of the trial to 52.0%p re d after 6 months. How e ve r, lung func tion remaine d unchanged in the FP group (mean FEV 1 : 72.4 and 69.1%pre d, re spe ctively). This treatme nt e ffec t w as statistically signific ant, and considered as a benefic ial effect of FP treatment.
Immunocytology
Me an total c ell numbe r of the BAL at the start of the trial w as 53.0´10 6 for FP treated patie nts and 45.3´10 6 in the plac ebo group (Table 2 ) . Small changes w ere notic ed in the BAL c ell numbers at the end of the trial, w hich w ere not significant ( Table 2 ). The pe rcentages of fluid re covery, c ell viability and ce ll types w e re not statistic ally different betw e en both patient groups, be fore interve ntion, and did not change signific antly afte r 6 months of inte rvention ( Table 2 ). The low number of eosinophils indic ates that COPD w as stable in nature . (Fig. 2, R= -0 .67, p = 0.007, Spearman rank te st). There w as no significant c orre lation of V m ax and packyears of smoking.
ROS production capability
Discussion
In this double blind, place bo c ontrolled trial, w e observe d no significant e ffec t of a pote nt inhale d gluc ocorticoid on the ROS produc tion c apability (V m a x ) of BAL ce lls de rived from a subgroup of COPD patients, namely those w ith bronchial hype rresponsivene ss. At first glance , this re sult appe ars to be related to the absenc e of a decre ase in the number of inflammatory c ells in the BAL. Our correlation studie s indicated that actual smoking status is an important confounding fac tor. With inc re asing numbe r of c igarettes smoked per day, V m a x de crease s.
As the re has not bee n published a similar study in COPD patients be fore, w e c ompared our re sults w ith studies c onc erning the effe cts of glucocorticoids on ROS production c ap ac ity of blood-derive d c ells, and w ith studies c onc erning the effect of smoking.
In one study, the superox ide produc tion by PMAstimulated blood granulocyte s, take n from 18 misce llane ous patie nts on oral glucocorticoid treatme nt, w as dec re ased as compared to healthy c ontrols. 8 Superox ide production by blood granulocytes of patients w ith emphyse ma w as decre ased afte r in v ivo prednisolone treatme nt. 9 How e ve r, dex amethasone, both in v itro and in v ivo , did not alter the spontane ous superox ide release of blood granulocyte s from he althy volunte ers. 1 0 The re porte d studies c onc erning the effe ct of smoking on ROS production c apability are not consis te nt. Alveolar macrophage s (AM) from healthy smokers produc ed more superox ide than AM from nonsmoking control subjec ts. 1 1-13 Ex posure to tobacco smoke in vitro inc re ased the ox idative me tabolism of AM, 14 w hile it re duce d superox ide generation by blood granuloc ytes. 15 Hoidal e t a l. used almost the same lavage me thod as in our study, and c ompared young asymptomatic smoke rs w ith nonsmoke rs. 1 1 The y re ported that BAL cells from smokers, stimulated w ith PMA, produc ed on ave rage 1.93 nmol ROS/min /10 6 c ells, w hile BAL ce lls from nonsmoke rs produc ed 0.945 nmol ROS/ min /10 6 ce lls. We found an average (pre-inte rvention ) ROS production of 0.322 nmol/min /10 6 cells (n = 15 ). The low ROS production capability in our study could either be due to patie nt se le ction (COPD), the pre sence of BHR, diffe rent BAL ce ll counts or to smoking. ROS production by BAL cells from smokers w ithout COPD w as not diffe re nt from smokers w ith COPD. 16 Therefore , the diagnosis of COPD se ems to be unimportant. Furthermore, since the leve l of PC20 w as not significantly correlated w ith V m a x , and the ce ll profile in BAL rese mble s the reporte d findings in 'average' COPD patie nts and smokers, the first three options are not likely. How e ve r, our corre lation analyses indicate that c igarette smoking influenc es ROS p roduc tion c apability. A possible ex planation c ould be that viable macrophage s lose the ir ability to release superox ide after repe ated stimulation. 1 7 This w as attributed to ligand-induced de se nsitisation of spe cific re ceptors. This p henome non might also have occ urred in our he avy smoking COPD patie nts.
In conclusion, the BAL cells from smoking COPD patients w ith BHR, c onsisting mainly of alveolar macrophage s, have a low ROS production capability. This w as not furthe r dec re ased by in v ivo ex posure to a potent inhaled gluc oc orticoid. The low ROS production c apability might be one of the causative mechanisms of the increase d susce ptibility to re spiratory tract infec tions and the increase d fre que ncy of bacte rial c olonisation of the airw ays in these COPD patie nts. 
Mediators of
